🔎 Trials Near Me

Beranda › Psoriasis › Pennsylvania

Uji klinis Psoriasis di Pennsylvania

6 studi untuk Psoriasis mencari peserta di lokasi di Pennsylvania.

Kota di Pennsylvania

Teks studi resmi (Bahasa Inggris)

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

  • LEO Pharma Investigational Site, Philadelphia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07013201

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  • Dermatology Associates of Plymouth Meeting, Plymouth Meeting
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06857942

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  • Paddington Testing Company, Philadelphia
Menerima pesertaFase 3
Usia 12 hingga 17 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06979453

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

  • Study Center, Philadelphia
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07489885

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

  • Temple University, Philadelphia
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jan 2025 · NCT05642182

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.